See the original post here:
Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh